Figure 6. In vitro effect of OGT2115 on pancreatic beta cells. (A) MIN6 cells were treated with different doses of OGT2115 for 24 h, and then cell viability was determined with the MTT assay (IC50=10.31 μM, n=5). (B) Cell viability of MIN6 cells treated with STZ (10 mmol/L) in the presence of different doses of OGT2115 for 24 h. ***p<0.001 as indicated, n=5. (C) Determination of glucose stimulated insulin secretion in the different treatment of murine islets for 24 h. ***p<0.001, ns=not significant as indicated, n=6; 10 islets per group. (D) Determination of mRNA levels of Insulin(Ins ), Pdx1 , and Mafa in the different treatment of murine islets for 24 h. ***p<0.001, ns=not significant as indicated, n=6. (E) Murine islets were incubated with different concentration of glucose for 24 h, the mRNA expression level ofHeparanase (Hpse ) in the murine islets was determined, n=6. *p< 0.05, **p< 0.01 compared to 11.1 mM glucose cultured group. (F) After 24 h treatment of different dose of STZ, the mRNA expression of Hpse in murine islets, n=6. (G) After 24 h treatment in 11.1 mM or 25 mM glucose, the mRNA expression levels ofPparg , Smad4 , Lef1 , p53 , Egr1 ,Ets1 , and Tgli1 in the murine islets. n=6. ***p< 0.001, ns=not significant as indicated.